A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(23 sites)

United States

Banner University Medical Center-Phoenix, Phoenix, Arizona

UC San Diego, La Jolla, California

Yale University, New Haven, Connecticut

University of South Florida, Tampa, Florida

Emory University, Atlanta, Georgia